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Abstract
Background: Information on factors that influence parental decisions for actual human papillomavirus (HPV) vaccine receipt
in publicly funded, school-based HPV vaccine programs for girls is limited. We report on the level of uptake of the first dose
of the HPV vaccine, and determine parental factors associated with receipt of the HPV vaccine, in a publicly funded school-
based HPV vaccine program in British Columbia, Canada.
Methods and Findings: All parents of girls enrolled in grade 6 during the academic year of September 2008–June 2009 in
the province of British Columbia were eligible to participate. Eligible households identified through the provincial public
health information system were randomly selected and those who consented completed a validated survey exploring
factors associated with HPV vaccine uptake. Bivariate and multivariate analyses were conducted to calculate adjusted odds
ratios to identify the factors that were associated with parents’ decision to vaccinate their daughter(s) against HPV. 2,025
parents agreed to complete the survey, and 65.1% (95% confidence interval [CI] 63.1–67.1) of parents in the survey reported
that their daughters received the first dose of the HPV vaccine. In the same school-based vaccine program, 88.4% (95% CI
87.1–89.7) consented to the hepatitis B vaccine, and 86.5% (95% CI 85.1–87.9) consented to the meningococcal C vaccine.
The main reasons for having a daughter receive the HPV vaccine were the effectiveness of the vaccine (47.9%), advice from
a physician (8.7%), and concerns about daughter’s health (8.4%). The main reasons for not having a daughter receive the
HPV vaccine were concerns about HPV vaccine safety (29.2%), preference to wait until the daughter is older (15.6%), and not
enough information to make an informed decision (12.6%). In multivariate analysis, overall attitudes to vaccines, the impact
of the HPV vaccine on sexual practices, and childhood vaccine history were predictive of parents having a daughter receive
the HPV vaccine in a publicly funded school-based HPV vaccine program. By contrast, having a family with two parents,
having three or more children, and having more education was associated with a decreased likelihood of having a daughter
receive the HPV vaccine.
Conclusions: This study is, to our knowledge, one of the first population-based assessments of factors associated with HPV
vaccine uptake in a publicly funded school-based program worldwide. Policy makers need to consider that even with the
removal of financial and health care barriers, parents, who are key decision makers in the uptake of this vaccine, are still
hesitant to have their daughters receive the HPV vaccine, and strategies to ensure optimal HPV vaccine uptake need to be
employed.
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The vaccine for the human papillomavirus (HPV) is an
important tool in the prevention of cervical cancer [1–5]. In
order to maximize the benefit of the HPV vaccine for cervical
cancer prevention and for programs to be cost-effective, vaccine
programs should be offered to girls prior to the commencement of
sexual activity [6–8]. Because of the age at which the HPV vaccine
is given in many jurisdictions, parents will often need to provide
consent. Careful reflection on parents’ perspectives and concerns
about this vaccine is essential in order to ensure optimal uptake
rates. Studies on parental attitudes and intention-to-vaccinate have
shown that despite the outstanding clinical efficacy and reassuring
side-effect profile of this vaccine, concerns remain about the
vaccine and about the willingness of parents to have their
daughters receive HPV vaccination [9–18]. In a recent systematic
review on the topic, global HPV vaccine acceptability among
parents ranged from 54.9% to 81.0% [19], and studies have
highlighted issues such as vaccine safety, impact on sexual
practices, age of daughter, awareness of HPV, education, and
cervical cancer screening history among many others as key
predictors of HPV vaccine acceptance. However, most studies
have primarily focused on factors predicting parental intention to
have a daughter receive the HPV vaccines and were conducted
prior to the approval of the HPV vaccine or implementation of a
publicly funded vaccine program. In contrast, data on factors
influencing parental decisions for actual or real HPV vaccine
receipt in publicly funded and delivered vaccine programs for girls
is limited [20]. As publicly funded HPV vaccines programs are
now being planned it is critical that parental factors associated
with actual uptake of the HPV vaccine are understood.
In Canada, health falls under provincial/territorial jurisdiction
and by September 2009, all of the 14 provinces and territories in
Canada commenced a school-based HPV vaccine program. In
September 2008, the province of British Columbia in Canada
embarked on a voluntary, school-based HPV vaccination program
for girls in grade 6 (aged 11 y) and grade 9 (aged 14 y) with
Gardasil. With the implementation of this program, and given the
critical role of parents in vaccine uptake and previous research that
indicated that British Columbians were less likely than Atlantic
Canadians to intend to have their daughters receive the HPV
vaccine [14], we took the opportunity to conduct a population-
based evaluation of the HPV vaccine program in the province. We
conducted a telephone survey of a random selection of parents of
grade 6 girls in the province who were eligible to receive the HPV
vaccine. The objective of this evaluation was to assess the level of
uptake of the first dose of the HPV vaccine and to determine the
factors associated with receipt of the HPV vaccine.
Methods
Participants and Data Collection
All parents of girls enrolled in grade 6 during the academic year
of September 2008–June 2009 in the province of British Columbia
were eligible to participate. Telephone numbers of eligible
households were identified through the integrated Public Health
information system (iPHIS) program. iPHIS is a software and
public health information system used by 14 of 16 Health Service
Delivery Areas of British Columbia for notifiable disease reporting,
as an immunization registry, and for vaccine-associated adverse
event reporting. iPHIS contains identifiers of all individuals who
have received a public health service, including well baby
examination, hearing and vision screening, and immunization
services. Phone numbers of households with a girl in grade 6 in the
province were identified as part of a comprehensive HPV vaccine
program evaluation, and households were randomly selected to be
contacted by telephone after the first dose of the HPV vaccine had
been offered through the school-based program and invited to
participate in this survey. Parents who consented were interviewed
by trained, experienced research staff. The evaluation received
ethical approval from University of British Columbia and funding
from the BC Centre for Disease Control.
HPV Vaccine Program in British Columbia
In British Columbia, all vaccines provided in schools, including
the HPV vaccine, are fully funded by the public health program in
the province. The vaccines are delivered as part of a comprehen-
sive school-based vaccination program for hepatitis B, meningo-
coccal C, tetanus-diphtheria, and acellular pertussis booster, as
well as a catch-up program for varicella zoster virus vaccine. In
2008, Gardasil was added to the school-based vaccine program in
British Columbia. Trained public health nurses offer these
vaccines in all public and independent schools through the entire
province free of cost, and in the grade 6 program, parents provide
consent for their daughters to receive, or not receive, HPV and
other vaccines. Children who are absent are able to receive
vaccines on days when the school nurses return for other classes, or
can attend local public health units to receive the vaccine free of
charge. Education for the HPV vaccine program focused on
cervical cancer prevention, and was widely promoted through the
schools with information packages and DVDs aimed at parents
and children. Public health nurses offered local educational
sessions where possible. Parents were also provided with the link
to www.immunizeBC.ca, which has extensive information on all
vaccines, including HPV.
Theoretical Model
The survey tool is based on the theoretical model of Theory of
Planned Behaviour (TPB) [21]. This psychological model of
behaviour change examines how human action is guided and
distils the elements that contribute to an actual behaviour (in this
case, consent to have a daughter receive the HPV vaccine), or the
most proximate measure of change, behaviour intention. Accord-
ing to TPB, behaviours or behavioural intentions are a result of
attitudes, subjective norms, and perceived behavioural control.
This well-established model provides a foundation for question-
naire development regarding health behaviours or behaviour
intentions. For this survey, we will examine the actual behaviour
(receipt of the vaccine) and discern parental factors that predict
vaccine uptake.
Survey Instrument Development
Questionnaire development adhered to the steps needed to
construct a TPB questionnaire and was based on a previous study
on intention to vaccinate [14]. The ‘‘population of interest’’ was
defined as parents of daughters in grade 6 in British Columbia,
and the ‘‘behaviour under examination’’ was parental consent (or
not) to have daughters receive the HPV vaccine. Behaviour was
measured by parental self-report as to whether or not they had
consented to have their daughter receive the HPV vaccine.
Perceived advantages and disadvantages of the HPV vaccine, most
important people/groups who would approve or disapprove of the
vaccine, and perceived barriers/facilitating factors were identified
through a comprehensive literature search, an elicitation survey of
ten parents to determine factors influential in their decision to
immunize or not to immunize their daughter(s) against HPV, and
results from intention to vaccinate studies [14]. A draft survey
including all constructs was pilot tested with parents to ensure
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missed. Parents identified questions on ‘‘barriers/facilitating
factors’’ for this vaccine program that were redundant and
confusing, as this was a publicly funded, provincial program
delivered at every school by school nurses, thus removing any
expected barriers such as cost and access to the program/
practitioners.
Survey Content
Demographics items assessed included age and gender of
respondent, region of residence, age(s) and number of daughters,
respondent education, cultural background, history of abnormal
Pap smears or cervical cancer, religious affiliation, and family
composition. Participants were asked about adherence to
childhood vaccination schedules and knowledge of cervical
cancer and HPV at the start of the survey. Participants were
next asked to report whether or not their daughter had received
the hepatitis B, meningococcal C, and HPV vaccine that year, as
well as the number of doses of the HPV vaccine received, and
intention to complete the series for the HPV vaccine. Parents
were asked to provide the main reason for electing to have their
daughter receive or not receive the HPV vaccine, as well as any
reason for their choice, and these reasons were categorized.
Participants were asked about specific psychological constructs
that could influence their decision to vaccinate or not vaccinate
their daughter with the HPV vaccine. In keeping with TPB,
these constructs included attitudes toward vaccines in general
and the HPV vaccine in particular, perceived impact of the HPV
vaccine on their daughter’s sexual practices, and the seriousness
of HPV infection and cervical cancer as diseases. These
constructs were assessed using seven-point Likert scales (1,
strongly disagree; 4, neutral; 7, strongly agree) with four or five
items per construct.
Sampling Frame and Telephone Recruitment
British Columbia is the most western province of Canada, with
a population of more than 4 million. It is divided into five
geographic health authorities and each health authority is divided
into health service delivery areas (HSDAs). There are a total of 16
HSDAs in the province, and each health authority has either three
or four HSDAs. Two of the HSDAs, which include ,15% of the
eligible girls in the province, do not use iPHIS, the provincial
immunization registry, as their public health information system
and thus were not included in the sampling frame. In order to
ensure a representative sample from across the province, we
generated a sampling frame from British Columbia population
estimates for each of the five geographic health authorities of 11-y-
old girls for 2008 from Population Extrapolation for Organization
Planning with Less Error, run cycle 32 (P.E.O.P.L.E. 32) [22],
excluding the two HSDAs not participating. P.E.O.P.L.E. 32 is the
subprovincial (local health authority, health region, regional
district, and development region) population projections that are
released annually by the BC government (BC Stats). P.E.O.P.L.E.
32 was released in 2007. Assuming a population of 20,000 girls in
the eligible age cohort, response rate of 50%, and a 95%
confidence interval (CI) of 62%, we needed to recruit 2,144
participants [23]. We randomly selected participants from the
datasets from each health authority, to ensure that at the end of
the evaluation we had a representative sample based on the
population size of 11-y-old girls in each health authority in the
province.
Telephone calls for the evaluation were conducted by an
experienced research company who had carried out previous
parental attitudinal surveys in British Columbia. Participants
were randomly selected from each health authority, and
households were contacted in the random order provided.
Households were called a maximum of four times, with attempts
to contact made in the morning, afternoon, evening, and
Saturdays. We stopped calling households once one of the
following occurred: participant declined; number not in service;
no answer after four attempts; messages left four times; or survey
not completed/ineligible.
Analysis
Descriptive analyses of sample demographics were conducted.
Item reliability was established for psychological construct scales
using Cronbach’s alpha, and mean values for each scale were
calculated. For scale items, composite scale scores were calculated
and dichotomized with a mean value of 4.5 as a cut-off, with scores
$4.5 indicating a general positive value for the HPV vaccine (i.e.,
a positive attitude to vaccines, belief that the HPV vaccine had
limited influence on sexual behaviour). Composite variables were
created for the predictor variables and dichotomized, and then
entered into the model as described in the methods. Bivariate
analyses were conducted using Chi-square comparing the
responses of parents who vaccinated their daughter(s) against
HPV to those who did not vaccinate. Variables that achieved
p,0.05 were offered for inclusion in a multivariable model to
achieve a best fit model. Logistic regression was conducted to
calculate adjusted odds ratios to identify the factors that were
associated with parents’ decision to vaccinate their daughter(s)
against HPV. Backwards logistic regression analysis was conducted
to calculate adjusted odds ratios to identify the factors that were
associated with parents’ decision to vaccinate their daughter(s)
against HPV. We also used additional backwards and forward
variable selection techniques to confirm that the model and
findings were robust (unpublished data). Analyses were conducted
with SPSS version 14.0 for Windows.
Results
This program evaluation was carried out between January 18,
2009, and March 19, 2009, 4 mo after the provincial HPV vaccine
program commenced. Of the 23,614 girls in grade 6 in the
province of British Columbia, contact information was available
for 20,161 from 14 of 16 health service areas (85.4%) in iPHIS.
5,489 of 20,161 eligible households, stratified by health authority,
were randomly contacted by the research team. Of the 4,335
numbers in service (78.9%), 304 did not speak English. Of the
remaining 4,031 eligible to complete the survey, 2,025 parents
agreed to complete the survey (50.2%).
Demographic characteristics of the participants are shown on
Table 1. The majority of survey respondents were female (84.9%),
most had given their daughters all childhood vaccinations (94.1%),
and more than 90% had heard of HPV. Respondents were
representative of the population distribution of grade 6 girls in
health authorities in the province, and 1,318 (65.1%; 95% CI
63.1–67.1) of parents in the survey reported that their daughters
had received the first dose of the HPV vaccine. In the same school-
based vaccine program, 1,790 (88.4%; 95% CI 87.1–89.7)
reported consenting to the hepatitis B vaccine, and 1,751
(86.5%; 95% CI 85.1–87.9) consented to the meningitis C vaccine.
In those who received the first dose of the HPV vaccine, 97.5%
said that they planned to have their daughter receive the next dose
of the HPV vaccine. Of the 34.9% of parents who did not consent
to have daughters receive the HPV vaccine, almost 50% stated
that they would prefer to have their daughter receive the HPV
vaccine in the future.
Evaluation of BC HPV Vaccine Program
PLoS Medicine | www.plosmedicine.org 3 May 2010 | Volume 7 | Issue 5 | e1000270Parents were asked to list both a main (single) reason and any
reason for their vaccine choice. The main reasons for having a
daughter receive the HPV vaccine were the effectiveness of the
vaccine (48.0%), advice from a physician (8.7%), and concerns about
their daughter’s health (8.3%) (Table 2). The main reasons for not
having a daughter receive the HPV vaccine were concerns about
HPV vaccine safety (30.0%), preference to wait until the daughter is
older (15.8%), and not enough information to make an informed
decision (12.5%). For those parents who indicated that they preferred
t oh a v et h e i rd a u g h t e rw a i ta se i t h e rt h e i rm a i no ro n eo ft h e i rr e a so n s
(n=337), morethan46.3% said thatthey felt they needed more safety
data, and 27.0% felt that their daughter was not at risk of sexual
activity in grade 6 but might be when they were older.
Internal reliability of the three psychological constructs using
Cronbach’s alpha were as follows (Table 3): 0.8, overall attitudes
to vaccines; 0.7, attitudes of the impact of the HPV vaccine on
sexuality; 0.5, seriousness of HPV disease/cervical cancer. In
bivariate analysis, age of respondent, country of birth, knowledge
of HPV, religious affiliation, history of abnormal Pap smears, and
history of cervical cancer were not associated with having a
daughter receive the HPV vaccine. Parents with higher levels of
education (more than high school diploma/vocational training)
were significantly less likely to consent to having their daughter
receive the HPV vaccine (63.3% versus 72.9%, p,0.01), and
parents from non-traditional families (i.e., families not headed by a
male and female) were more likely to have their daughters receive
the HPV vaccine (71.6% versus 63.1%, p,0.01) (Table 4). We did
our analysis plan such that variables inputted into the model had
to achieve significance in the bivariate model. In multivariate
analysis, overall attitudes to vaccines, impact of the HPV vaccine
on sexual practices, and childhood vaccine history were predictive
of parents having daughter’s receive the HPV vaccine in a publicly
funded school-based HPV vaccine program. In contrast, having a
family with two parents, having three or more children, and
having more education was associated with a decreased likelihood
of having a daughter receive the HPV vaccine (Table 5).
Discussion
This program evaluation offers important insights into factors
that are associated with parental decisions about receipt of the
Table 1. Demographic characteristics of survey respondents.
Characteristics of Respondents (n=2,025) n (%)
Respondents’ gender
Female 1,719 (84.9)
Male 301 (14.9)
No response 5 (0.2)
Age of respondents (y)
19–29 17 (0.8)
30–39 632 (31.2)
40–49 1,135 (56.0)
50–59 189 (9.3)
60+ 15 (0.7)
No response 37 (1.8)
Child received all childhood vaccines
Yes (all) 1,903 (94.1)
Yes (some) 82 (4.1)
Unsure 8 (0.4)
No 30 (1.5)
Ever heard of HPV
Yes 1,878 (92.7)
No 147 (7.3)
History of cervical cancer (self or partner)
Yes 80 (4.0)
No 1,906 (94.1)
Unsure/missing 39 (1.9)
History of abnormal Pap smear (self or partner)
Yes 700 (34.6)
No 1,274 (62.9)
Unsure/missing 51 (2.5)
Education
High school education/vocational school 713 (35.9)
Some or complete undergraduate degree 1,119 (55.3)
Postgraduate degree 156 (7.7)
Missing 37 (.8)
Family composition
Single parent/guardian 252 (12.4)
Two parents (male/female) 1,513 (74.7)
Parents/guardians extended family 92 (4.5)
Blended families 128 (6.3)
Missing 40 (2.0)
Number of children
One or two children 1,297 (64.0)
Three of more children 728 (36.0)
Country of birth
Canada 1,544 (76.2)
England 54 (2.7)
China 15 (0.7)
India 64 (3.2)
Philippines 39 (1.9)
United States 47 (2.3)
Germany 16 (0.8)
Other 246 (12.1)
Characteristics of Respondents (n=2,025) n (%)
Religious background
Christian (Catholic or Protestant) 327 (16.2)
Christian (other) 440 (21.7)
Sikh 47 (2.3)
Muslim 18 (0.9)
Buddhist 12 (0.6)
Evangelical Christian 8 (0.3)
Jewish 3 (0.1)
Other religion (including other Christian denominations) 476 (23.5)
None 694 (43.3)
Organized religion
No religious affiliation 632 (31.2)
Religious affiliation 1,393 (68.8)
doi:10.1371/journal.pmed.1000270.t001
Table 1. Cont.
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the cost of the vaccine nor access to health care are barriers. In this
population-based evaluation of a publicly funded, school-based
HPV vaccine program for girls aged 11 y in Canada, parents
reported that 65.1% of eligible girls received the first dose of the
HPV vaccine, compared to reported receipt of 88.4% for the
hepatitis B vaccine, and 86.5% for the meningitis C vaccine.
Parents cited vaccine efficacy, advice from a physician, and
concerns about daughters’ health as the main reasons for choosing
to have daughters receive the vaccine. In contrast, concerns about
vaccine safety, a desire to wait until their daughter was older, and
lack of information were main reasons for not having daughters
receive the vaccine. In multivariate modeling, overall attitudes to
vaccines and the HPV vaccine, limited concern about the
influence of the HPV vaccine on sexual behaviour, and receiving
childhood vaccines were associated with having a daughter receive
the HPV vaccine. In contrast, family composition (two parents),
having more children, and higher education were associated with
not having a daughter receive the HPV vaccine. Of note, none of
the following factors were associated with decisions to receive the
HPV vaccine: religious affiliation, country of birth, or a self-
reported history of abnormal Pap smears or cervical cancer.
In a previous study [14], parental intention to have daughters
receive the HPV vaccine in British Columbia was 62.8% (95% CI
60.2–65.4), which approximates both the reported parental uptake
in this current study at 65.1% and first dose HPV vaccine uptake
reported in the provincial clinical immunization record in the
province for 2008 of 64.8% [24]. This finding indicates that
intention to vaccinate studies can be very useful in planning for
actual uptake of the HPV vaccine, albeit with limitations.
Comparing the intention to vaccinate [14] with our study, some
common factors emerge as key predictors of intention to vaccinate
and actual vaccination. These factors included overall attitudes to
vaccines and role of the HPV vaccine on sexual behaviour. In our
study of actual HPV vaccine uptake, previous actions around
vaccines, including childhood vaccine history, were positively
associated with the decision to have daughters receive the HPV
vaccine. A higher level of parental education and more traditional
family composition, including greater numbers of children and
two-parent families, were associated with a decision to not have
Table 2. Reasons for having daughters receive or not receive HPV vaccine.
Reasons for HPV Vaccination Acceptance or Nonacceptance Main Reason n (%) Any Reason n (%)
Reasons for Having Daughter Receive HPV Vaccine (n=1,289)
Vaccine is effective in preventing cancer/HPV 619 (48.0) 827 (64.2)
Physician advised me 112 (8.7) 149 (11.6)
Concerned about daughter’s health 107 (8.3) 280 (21.7)
Consent to all vaccines, HPV no different 92 (7.1) 158 (12.3)
Public health nurse advised me 80 (6.2) 111 (8.6)
Family member/friend with cervical cancer 40 (3.1) 40 (3.1)
Important to vaccinate prior to sexual activity 32 (2.5) 109 (8.5)
Cervical cancer is a serious disease 30 (2.3) 109 (.8.5)
HPV vaccine is a safe vaccine 23 (1.8) 53 (4.1)
Trust our health care system 18 (1.4) 69 (5.4)
Friend/family/self had cancer 17 (1.3) 17 (1.3)
Benefit outweighed risk 12(0.9) 12 (0.9)
Other 107 (8.3)
Main reasons for NOT having daughter receive HPV vaccine (n=697)
Safety of the vaccine 209 (30.0) 295 (42.3)
Prefer to wait until daughter is older 110 (15.8) 303 (43.5)
Not enough information to make an informed decision 87 (12.5) 148 (21.2)
Vaccine is too new 50 (7.2) 50 (7.2)
Daughter not at risk of cervical cancer 37 (5.3) 88 (12.6)
I do not believe in vaccines, HPV no different 18 (2.6) 25 (3.6)
My physician advised me not to have daughter receive it 17 (2.4) 22 (3.2)
Daughter is too young 14 (2.0) 14 (2.0)
More research needed 13 (1.9) 13 (1.9)
Daughter is not sexually active 13 (1.9) 13 (1.9)
Vaccine is a ploy by pharmaceutical company 12 (1.7) 30 (4.3)
Consent will encourage sexual activity 11 (1.5) 31 (4.4)
Will educate daughter on abstinence and safe sex 10 (1.4) 10 (1.4)
Too many needles 10 (1.4) 21 (3.0)
Other 86 (12.3)
doi:10.1371/journal.pmed.1000270.t002
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the intention to vaccinate survey, underscoring the importance of
examining actual rather than intended behaviour.
This evaluation has important implications broadly for HPV
vaccine policy, because there were neither financial nor organi-
zational barriers to receipt of the HPV vaccine in this program.
The vaccine program was fully funded for all girls in grade 6 and
was delivered in schools throughout British Columbia as part of a
well-established school-based immunization program. Despite this
access to the program, almost 35% of parents elected not to have
their daughters receive the HPV vaccine. In an examination of
parents of almost 3,000 girls aged 12 and 13 y in Manchester,
United Kingdom, vaccine uptake was 70.6% for the first dose
[20], and parents identified vaccine safety and long term data as a
key factor in vaccine refusal. In a qualitative study of 52 parents,
Dempsey et al. found that parents identified lack of knowledge,
safety, and a perception that their daughter was too young as
factors associated with declining of the HPV vaccine [25]. In a
study of 153 mothers that included both those intending to have
daughters vaccinated and those who had vaccinated their
daughters, less education, parental history of a sexually transmitted
infection, parental supervision, and acceptance of the vaccine
schedule were associated with HPV vaccine acceptance [26]. The
findings of these studies echo those found in this study in which
parents expressed concerns about the long term safety of the HPV
vaccine as a primary reason for refusing to have daughters
vaccinated. Parents who did not permit their daughters to receive
the vaccine were also concerned about the young age of their
daughters, believed the vaccine condoned sexual activity, or
believed their daughter was at low risk for acquiring HPV. It is
noteworthy that in British Columbia, prior to implementation of
the HPV vaccine program, one of the most comprehensive vaccine
education programs to date for the province was implemented.
These efforts targeted issues such as vaccine safety and efficacy and
were delivered in several user-friendly formats including the www.
immunizeBC.ca Web site, through DVDs targeted at parents and
girls, as well as with pamphlets and brochures and locally held
information sessions for parents and providers. In addition, this
vaccine was strongly recommended by several independent expert
health groups, such as the Canadian National Advisory Commit-
tee on Immunizations [27]. However, despite these efforts, many
parents still perceived that information was inadequate for them to
make an informed decision about HPV vaccination.
In keeping with the findings of two recent studies, this evaluation
noted that parents with more education were less likely to consentto
their daughters receiving the HPV vaccine [17,26]. This is a
surprising outcome, and in contrast to most studies on vaccine rates
in children and maternal education, where higher maternal
education is associated with higher childhood vaccine rates [28].
Thereareseveraldifferencesto consideraswecompare ourfindings
to existing literature. The HPV vaccine program in British
Columbia is delivered in optimal conditions with limited barriers,
and so several of the issues that may cause lower uptake rates in less-
educated parents in other jurisdictions may not be operating for this
program. Specifically, the HPV vaccine program in British
Columbia is part of a well-established adolescent school-based
vaccine program, where vaccines are offered at school, during
school hours, by trained health professionals. As a result, parents do
not need to get prescriptions, leave work, or arrange to bring
children to an office or clinic to receive the vaccine. Parents do not
need to pay for the vaccine, so there are no financial constraints for
parents. Nurses return to schools several times so that children have
the opportunities on other occasions to receive their vaccinations.
Our evaluation examined uptake of vaccines in an adolescent as
opposed to infant/toddler population, so some of the previous
findings and underpinning barriers for infants/toddlers may not be
Table 3. Results of psychological construct scales.
Psychological Construct Scale Results Mean (Standard Deviation)
Attitudes to vaccines and HPV vaccine overall
Childhood vaccines are beneficial 6.1 (1.1)
HPV vaccine is beneficial 5.4 (1.4)
HPV vaccine is effective in preventing cervical cancer 5.3 (1.4)
Immunization is important for public health 6.4 (1.0)
HPV vaccine is a safe vaccine 5.1 (1.5)
Overall mean 5.6 (1.0)
Influence of HPV vaccine on sexual behaviour
Need to give HPV vaccine prior to sexual activity 5.7 (1.6)
HPV vaccine does not lead to earlier sexual activity 5.9 (1.5)
HPV vaccine does not lead to unsafe sexual practices 5.7 (1.6)
HPV vaccine does not lead to more sexual partners 5.9 (1.5)
Safe sex at all times prevents acquisition of HPV 4.7 (1.9)
Overall mean 5.5 (1.1)
Risk for and seriousness of HPV and cervical cancer
Likely for someone you know to get cervical cancer 5.2 (1.7)
Cancer of cervix is a serious illness 6.7 (0.7)
Cervical dysplasia is a serious health concern 6.4 (0.9)
Safe sex at all times prevents acquisition of HPV 6.2 (1.1)
Overall mean 6.1 (0.7)
doi:10.1371/journal.pmed.1000270.t003
Evaluation of BC HPV Vaccine Program
PLoS Medicine | www.plosmedicine.org 6 May 2010 | Volume 7 | Issue 5 | e1000270as relevant. This evaluation also examined a newly launched as
opposed to a well-established vaccine, and so the factors operating
in parental decision making may also be different.
Literature has noted that, in settings with low childhood vaccine
uptake rates in less-educated mothers, programmatic structures can
reduce the impact of maternal educationon vaccine uptake rates. In
a recent review by Racine [28], higher maternal education,
independent of income and race/ethnicity, was associated with
higher child immunization rates. He found, however, that in
jurisdictions where there were greater subsidies for childhood
vaccines, there was a significantly smaller difference between rates
of immunization in children of less versus more educated mothers.
This analysis of US data proposed that with increased public
funding for vaccines, many of the barriers that create the
immunization rate gradient, such as price and availability, decline
in their importance, and the advantages offered by maternal
education with respect to childhood vaccine receipt are attenuated.
In a setting such as British Columbia, where there are even more
programmatic advantages such as offering the vaccine in the school
setting, the factors that lead to lower uptake rates in less-educated
parents in other settings may be diminished by the organization of
the adolescent immunization program in the province.
Further research and examination is needed to understand this
unique relationship. In a recent qualitative study on Texan parents
who opt out of childhood vaccine programs, Gullion et al. noted
that the parents were highly educated and reported very
sophisticated data collection and information processing from a
variety of sources including online sources [29]. Educated parents
are often more likely to have access to the Internet and other forms
of media compared with less-educated parents in the province,
and may feel more comfortable researching the Internet for
vaccine information. This research may increase access to some of
the Web sites that provide contradictory and potentially inaccurate
information about the HPV vaccine and increase parents’
concerns about vaccine risks. Highly educated parents may also
perceive that they are able to interpret complex scientific and
clinical health information and trials independently without the
assistance of practitioners. In Gullion’s work, parents reported
high distrust of the medical community and felt that they were
better equipped to conduct research on vaccines and more
knowledgeable than the medical practitioners on the topic of
vaccines [29]. Educated parents may also have felt more
comfortable delaying their daughters’ vaccination beyond aged
12 y as they would be able to purchase the vaccine privately in the
future, should they choose to do so. Guillon’s study noted that
parents often felt rushed regarding decisions around vaccines, and
so the perceived opportunities for discussion about the attributes
and risks of vaccines were limited. Clearly, there is a need for
further exploration of this topic to understand why educated
parents chose to decline the HPV vaccine for their daughters. As
educated parents can often be opinion leaders within their
Table 4. Bivariate analysis of uptake rate of HPV vaccine in
population.
Characteristics of Respondents
Daughter Received HPV
Vaccine n (%)
Respondents’ gender
Female 1,122 (65.3)
Male 192 (63.8)
Age of respondents (y)
19–29 16 (94.1)
30–39 438 (69.3)
40–49 703 (61.9)
50–59 126 (66.7)
60+ 11 (73.3)
Child received all
childhood vaccines
Yes (all) 1,280 (67.3)
Yes (some) 29 (35.4)
Unsure 7 (87.5)
No 1 (3.3)
Ever heard of HPV
Yes 1,213 (64.6)
No 105 (71.4)
History of cervical cancer
(self or partner)
Yes 61 (76.3)
No 1,231 (64.6)
Unsure/missing 8 (66.6)
History of abnormal Pap smear
(self or partner)
Yes 476 (68.0)
No 807 (63.3)
Unsure/missing 16 (69.6)
Education
High school/vocational school 493 (69.1)
Some/complete undergraduate
degree/college
700 (62.6)
Postgraduate degree 100 (64.1)
Family composition
Traditional (two parents, male
and female)
954 (63.1)
Nontraditional 338 (71.6)
Number of children
One or two children 878 (67.7)
Three or more children 440 (60.4)
Country of birth
Canada 999 (64.7)
England 33 (61.1)
China 10 (66.7)
India 50 (78.1)
Philippines 29 (74.4)
United States 29 (61.7)
Germany 11 (68.8)
Other 157 (63.8)
Characteristics of Respondents
Daughter Received HPV
Vaccine n (%)
Organized religion
No religious affiliation 439 (69.5)
Religious affiliation 879 (63.1)
doi:10.1371/journal.pmed.1000270.t004
Table 4. Cont.
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consider ways to ensure that these parents have accurate
information about this and other vaccines, and appropriately
contextualize vaccine risk and safety with the risks and sequelae of
the vaccine-preventable disease.
Parents who were concerned about the potential impact of the
HPV vaccine on sexual practices were less likely to have their
daughters receive the HPV vaccine. Over the past 10 y, British
Columbia has had a hepatitis B vaccine program for 11-y-old girls
and boys. In the corresponding time period, the Canadian
provincial adolescent health survey has reported an improvement
in sexual practices in adolescents, with delayed sexual debut, as
well as safer sexual practices, despite the availability of a vaccine
for a sexually transmitted infection in a publicly funded school
program in the province [30]. It will be critical to ensure that
parents are aware that provincial data have shown that the use of a
vaccine for a sexually transmitted infection does not increase risky
sexual behaviour.
The goal of this evaluation was to inform, in real time, vaccine
promotion efforts in the province of British Columbia to ensure
that educational efforts responded to the concerns of the
population. From this survey, it is clear that messaging should
continue to focus on the effectiveness of the HPV vaccine, and
continue to highlight the established safety of the HPV vaccine, as
well as the importance and safety of vaccines in general. Health
professionals remain central in influencing parents’ decision
around the HPV vaccine, and education should also target
physicians and nurses to ensure that they also possess accurate
information for parents who seek their council. Parents need to be
aware that the use of a vaccine for a sexually transmitted infection
(hepatitis B) over the past 10 y in British Columbia has not
adversely affected the sexual health of adolescents [30]. In
contrast, during this same time period, they appear to be making
better sexual health decisions.
Limitations of this study include our inability to access parents
in two health service areas that account for ,15% of the
Table 5. Multivariate analysis of factors associated with parents’ decision to have daughters receive the HPV vaccine in a publicly
funded HPV vaccine program.
Factors Associated with HPV Vaccine Uptake Unadjusted Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)
Childhood vaccine history
Received some or no childhood vaccines 1.0 1.0
Received all childhood vaccines 3.9 (2.6–5.9) 1.7 (1.1–2.5)
Education of respondent
High school/vocational school 1.0 1.0
Some/complete undergraduate degree/college 0.7 (0.6–0.9) 0.6 (0.5–0.8)
Postgraduate degree 0.8 (0.6–1.1) 0.6 (0.4–0.9)
Family composition
Nontraditional family composition 1.0 1.0
Traditional family composition 0.7 (0.5–0.8) 0.7 (0.5–0.9)
Number of children
One or two children 1.0 1.0
Three or more children 0.7 (0.6–0.9) 0.8 (0.6–0.9)
Part of organized religion
No religious affiliation 1.0 —
Religious affiliation 0.7 (0.6–0.9) —
Attitudes to HPV vaccine and vaccines overall
Negative attitudes to vaccines 1.0 1.0
Positive attitudes to vaccines 12.0 (8.8–16.4) 8.5 (6.1–11.9)
Impact of HPV vaccine on sexual practices
Negative impact on sexual practices 1.0 1.0
Limited impact on sexual practices 6.8 (5.3–8.7) 5.1 (3.9–6.7)
Seriousness of cervical cancer and HPV disease
Cervical cancer/HPV disease not serious 1.0 —
Cervical cancer/HPV disease serious 1.7 (1.1–2.6) —
Hepatitis B vaccine received with HPV vaccine
No hepatitis B vaccine received 1.0 —
Hepatitis B vaccine received 1.1 (1.0–1.2) —
Meningitis C vaccine received with HPV vaccine
No meningitis C vaccine received 1.0 —
Meningitis C vaccine received 1.0 (1.0–1.1) —
doi:10.1371/journal.pmed.1000270.t005
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methodology. Although there were quality assurance interviews
both at training with a random review of telephone calls by
supervisors and individual quality assurance reviews for data entry,
participants were not surveyed twice. Telephone surveys are
biased towards English speakers, and there were 304 potential
households who could not participate in this evaluation because of
a language barrier. However, this was not a random digit survey,
and we were able to use telephone numbers provided to public
health services by parents, so biases towards access to land lines
should be greatly diminished. Regardless, the reported HPV
vaccine uptake rate in this evaluation mirrored the uptake rate
reported through the provincial clinical immunization record in
the province of 64.8% [24]. With a population-based, randomly
selected sample of over 2,000, representing almost 10% of the
eligible population for the program, we expect these findings to be
highly generalizable and informative for HPV vaccine policies in
high-income countries worldwide.
This study is one of the first population-based assessments of
factors associated with HPV vaccine uptake in a publicly funded
school-based program worldwide. Policy makers need to consider
that even with the removal of financial and health care barriers,
parents, who are key decision makers in the uptake of this vaccine,
still possess some hesitancy to have their daughters receive the
HPV vaccine. As populations become less familiar with the
diseases that vaccines prevent and the sequelae of these diseases,
there is a greater focus on the adverse events associated with
vaccines, without the consideration of the morbidity and mortality
associated with the disease itself, nor the burden of disease averted
by the vaccine [31]. The experience with the HPV vaccine
highlights the continued need to ensure that the public is informed
and receives credible and clear information about both the
scientific evidence for immunizations, as well as information about
adverse events associated with vaccines in context. Use of the news
media, including the Internet, is essential for connecting with the
population, and policy makers must ensure that information
speaks broadly to the overall benefits of vaccines at a population
and individual level, as well as highlighting the attributes of
particular vaccines.
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Background. About 10% of cancers in women occur in the
cervix, the structure that connects the womb to the vagina.
Every year, globally, more than a quarter of a million women
die because of cervical cancer, which only occurs after the
cervix has been infected with a human papillomavirus (HPV)
through sexual intercourse. There are many types of HPV, a
virus that infects the skin and the mucosa (the moist
membranes that line various parts of the body, including the
cervix). Although most people become infected with HPV at
some time in their life, most never know they are infected.
However, some HPV types cause harmless warts on the skin
or around the genital area and several—in particular, HPV 16
and HPV 18, so-called high-risk HPVs—can cause cervical
cancer. HPV infections are usually cleared by the immune
system, but about 10% of women infected with a high-risk
HPV develop a long-term infection that puts them at risk of
developing cervical cancer.
Why Was This Study Done? Screening programs have
greatly reduced cervical cancer deaths in developed
countries in recent decades by detecting the cancer early
when it can be treated; but it would be better to prevent
cervical cancer ever developing. Because HPV is necessary for
the development of cervical cancer, vaccination of girls
against HPV infection before the onset of sexual activity
might be one way to do this. Scientists recently developed a
vaccine that prevents infection with HPV 16 and HPV 18 (and
with two HPVs that cause genital warts) and that should,
therefore, reduce the incidence of cervical cancer. Publicly
funded HPV vaccination programs are now planned or
underway in several countries; but before girls can receive
the HPV vaccine, parental consent is usually needed, so it is
important to know what influences parental decisions about
HPV vaccination. In this study, the researchers undertake a
telephone survey to determine the uptake of the HPV
vaccine by 11-year-old girls (grade 6) in British Columbia,
Canada, and to determine the parental factors associated
with vaccine uptake; British Columbia started a voluntary
school-based HPV vaccine program in September 2008.
What Did the Researchers Do and Find? In early 2009,
the researchers contacted randomly selected parents of girls
enrolled in grade 6 during the 2008–2009 academic year and
asked them to complete a telephone survey that explored
factors associated with HPV vaccine uptake. 65.1% of the
2,025 parents who completed the survey had consented to
their daughter receiving the first dose of HPV vaccine. By
contrast, more than 85% of the parents had consented to
hepatitis B and meningitis C vaccination of their daughters.
Nearly half of the parents surveyed said their main reason for
consenting to HPV vaccination was the effectiveness of the
vaccine. Conversely, nearly a third of the parents said
concern about the vaccine’s safety was their main reason
for not consenting to vaccination and one in eight said they
had been given insufficient information to make an informed
decision. In a statistical analysis of the survey data, the
researchers found that a positive parental attitude towards
vaccination, a parental belief that HPV vaccination had
limited impact on sexual practices, and completed childhood
vaccination increased the likelihood of a daughter receiving
the HPV vaccine. Having a family with two parents or three
or more children and having well-educated parents
decreased the likelihood of a daughter receiving the vaccine.
What Do These Findings Mean? These findings provide
one of the first population-based assessments of the factors
that affect HPV vaccine uptake in a setting where there are
no financial or health care barriers to vaccination. By
identifying the factors associated with parental reluctance
to agree to HPV vaccination for their daughters, these
findings should help public-health officials design strategies
to ensure optimal HPV vaccine uptake, although further
studies are needed to discover why, for example, parents
with more education are less likely to agree to vaccination
than parents with less education. Importantly, the findings of
this study, which are likely to be generalizable to other high-
income countries, indicate that there is a continued need to
ensure that the public receives credible, clear information
about both the benefits and long-term safety of HPV
vaccination.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000270.
N The US National Cancer Institute provides information
about cervical cancer for patients and for health profes-
sionals, including information on HPV vaccines (in English
and Spanish)
N The US Centers for Disease Control and Prevention also has
information about cervical cancer and about HPV
N The UK National Health Service Choices website has pages
on cervical cancer and on HPV vaccination
N More information about cervical cancer and HPV vaccina-
tion is available from the Macmillan cancer charity
N ImmunizeBC provides general information about vaccina-
tion and information about HPV vaccination in British
Columbia
N MedlinePlus provides links to additional resources about
cervical cancer (in English and Spanish)
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